Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Infectious Diseases
Volume 2018 (2018), Article ID 3297531, 3 pages
https://doi.org/10.1155/2018/3297531
Case Report

Chronic Tenosynovitis due to Mycobacteria kansasii in an Immunocompetent Host

1Department of Medicine, Lakeland Health, St. Joseph, MI, USA
2Osteopathic Medical Specialties, College of Osteopathic Medicine, Michigan State University, Lansing, MI, USA
3Department of Surgery, Lakeland Health, St. Joseph, MI, USA
4Infection Prevention, Lakeland Health, St. Joseph, MI, USA
5Department of Pathology, Lakeland Health, St. Joseph, MI, USA

Correspondence should be addressed to Michael S. Wang; gro.cmws@gnawm

Received 25 January 2018; Accepted 29 March 2018; Published 16 April 2018

Academic Editor: Larry M. Bush

Copyright © 2018 Michael S. Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. C. Bloch, L. Zwerling, M. J. Pletcher et al., “Incidence and clinical implications of isolation of Mycobacterium kansasii: results of a 5-year, population-based study,” Annals of Internal Medicine, vol. 129, no. 9, pp. 698–704, 1998. View at Publisher · View at Google Scholar
  2. D. E. Griffith, B. A. Brown-Elliott, J. Richard, and R. J. Wallace, “Thrice-weekly clarithromycin-containing regimen for treatment of Mycobacterium kansasii lung disease: results of a preliminary study,” Clinical Infectious Diseases, vol. 37, no. 9, pp. 1178–1182, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. J. C. Tompkins and R. S. Witzig, “Mycobacterium kansasii in HIV patients: clarithromycin and antiretroviral effects,” International Journal of Tuberculosis and Lung Disease, vol. 11, no. 3, pp. 331–337, 2007. View at Google Scholar
  4. M. J. Bittner, E. A. Horowitz, T. J. Safranek, and L. C. Preheim, “Emergence of Mycobacterium kansasii as the leading mycobacterial pathogen isolated over a 20-year period at a midwestern Veterans Affairs hospital,” Clinical Infectious Diseases, vol. 22, no. 6, pp. 1109-1110, 1996. View at Publisher · View at Google Scholar · View at Scopus
  5. L. Bernard, V. Vincent, O. Lortholary et al., “Mycobacterium kansasii septic arthritis: French retrospective study of 5 years and review,” Clinical Infectious Diseases, vol. 29, no. 6, pp. 1455–1460, 1999. View at Publisher · View at Google Scholar · View at Scopus
  6. D. H. M. Joynson, “Water: the natural habitat of Mycobacterium kansasii?Tubercle, vol. 60, no. 2, pp. 77–81, 1979. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Wada, S. Nomura, and F. Ihara, “Mycobacterium kansasii flexor tenosynovitis presenting as carpal tunnel syndrome,” Journal of Hand Surgery, vol. 25, no. 3, pp. 308–310, 2000. View at Publisher · View at Google Scholar · View at Scopus
  8. Z. Thierry, A. Bobieux, S. Tigaud et al., “Non-tuberculous mycobacterial tenosynovitis: a review,” Scandinavian Journal of Infectious Diseases, vol. 31, no. 3, pp. 221–228, 1999. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Aboudola, A. Sienko, R. B. Carey, and S. Johnson, “Tuberculosis tenosynovitis,” Human Pathology, vol. 35, no. 8, pp. 1044–1046, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. M. M. Johnson and J. A. Odell, “Nontuberculous mycobacterial pulmonary infections,” Journal of Thoracic Disease, vol. 6, no. 3, pp. 210–220, 2014. View at Google Scholar
  11. B. A. Brown-Elliot, K. A. Nash, and R. J. Wallace, “Antimicrobial susceptibility testing, drug resistance mechanisms and therapy of infections with nontuberculous mycobacteria,” Clinical Microbiology Reviews, vol. 25, no. 3, pp. 545–582, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. G. L. Woods, “Susceptibility testing for mycobacteria,” Clinical Infectious Diseases, vol. 31, no. 5, pp. 1209–1215, 2000. View at Publisher · View at Google Scholar · View at Scopus
  13. R. J. Wallace, D. Dunbar, B. A. Brown et al., “Rifampin-resistant Mycobacterium kansasii,” Clinical Infectious Diseases, vol. 18, no. 5, pp. 736–743, 1994. View at Publisher · View at Google Scholar · View at Scopus
  14. M. A. S. Telles and M. D. Yates, “Single and double drug susceptibility testing of Mycobacterium avium complex and mycobacteria other than the tubercle (MOTT) bacilli by a micro-dilution broth minimum inhibitory concentration (MIC) method,” Tubercle and Lung Disease, vol. 75, no. 4, pp. 286–290, 1994. View at Publisher · View at Google Scholar · View at Scopus
  15. C.-N. Lee and L. B. Heifts, “Determination of minimal inhibitory concentrations of antituberculosis drugs by radiometric and conventional methods,” American Review of Respiratory Disease, vol. 136, no. 2, pp. 349–352, 1987. View at Publisher · View at Google Scholar · View at Scopus